Pfizer's mRNA flu vaccine worked better than a standard flu shot in a large Phase 3 trial, researchers reported in the ...

In a Phase 3 trial of more than 18,000 volunteers across three countries, an mRNA influenza vaccine from Pfizer has ...

The new trial, funded by Pfizer, compared the company’s mRNA shot to Fluzone, one of the most widely used seasonal flu ...

Pfizer has released the full data from its phase 3 trial of an mRNA flu vaccine candidate, with the potential new shot demonstrating 34.5% greater efficacy compared to a control vaccine. | Pfizer has ...

The mRNA platform offers the advantage of faster vaccine production, which could allow more time to decide on which flu strains to cover.

mRNA vaccines can enhance immunotherapy efficacy by activating the immune system, improving outcomes in hard-to-treat tumors. mRNA COVID-19 vaccines enhance immune responses, improving cancer ...

The experimental mRNA vaccine prevented 60% to 67% of flu infections, while the conventional vaccine prevented 44% to 54% of ...

For people younger than 65, U.S.-licensed flu vaccines had an estimated effectiveness of 44% to 54% that season. Among those ...

Moderna is currently in the middle of an aggressive cost-cutting campaign. In September last year, the company announced that ...

A phase 3 trial found a modified mRNA influenza vaccine provided superior protection against influenza like illness in adults ...

Researchers at MIT have just developed a new lipid nanoparticle that super-enhances the effectiveness of the mRNA vaccine in ...

New research found that mRNA vaccines for COVID-19 could enhance cancer treatments and help patients live longer.